Health

Daraxonrasib combined with chemotherapy stops tumor growth in 90% of pancreatic cancer patients

A trial of 61 participants with advanced pancreatic cancer found that daraxonrasib combined with chemotherapy stopped tumor growth in 90% of patients. Dr. Wungki Park reports that over 60% of participants experienced tumors that either shrank or disappeared entirely during the study.

Daraxonrasib combined with chemotherapy stops tumor growth in 90% of pancreatic cancer patients

Trial results for daraxonrasib

In a trial of 61 participants with advanced pancreatic cancer that had spread to other parts of the body, daraxonrasib combined with chemotherapy caused tumours to stop growing in 90% of patients. In one in 12 cases, cancer became undetectable on CT scans for the patients given daraxonrasib along with chemotherapy. Just over 60% of participants in the trial experienced tumours that either shrank or disappeared entirely. The drug works by shutting off RAS mutations. This medication may also help patients with lung or ovarian cancers that share these mutations. Dr. Wungki Park from Memorial Sloan Kettering Cancer Center says the results show higher response rates, deeper responses, and a near doubling in the duration of disease control, which may eventually translate into longer survival. The trial followed participants for an average of a year and a half, and some did not see their cancer return during this time.

Limitations and survival rates

Cancer Research UK calls this development the biggest leap forward in decades for pancreatic cancer patients. Dr. Sam Godfrey of Cancer Research UK says the results are incredibly exciting and the drug found a way of "drugging the undruggable." In Britain, 11,500 people are diagnosed with pancreatic cancer every year, resulting in 10,200 deaths. The disease is deadly, as seen when actor Alan Rickman died in 2016, five months after receiving his diagnosis. This treatment is not a cure. While chemotherapy can shrink tumours slightly, the cancer often grows again, and most patients with advanced disease survive only months rather than years. Doctors need longer studies because cancer can return even if scans show no sign of it, meaning you do not know if a patient is cancer-free until more time passes. Dr. Godfrey hopes this early success seen in pancreatic cancer can also be rolled out to help patients with other cancers. Prof. Elena Garralda, chair of the European cancer conference EORTC, says the combined treatment could potentially improve overall survival. Symptoms of the disease include jaundice, itchy skin, darker urine, paler stools, unexplained weight loss, tiredness, and a high temperature.